Tongji University

About: Tongji University is a education organization based out in Shanghai, China. It is known for research contribution in the topics: Computer science & Population. The organization has 76116 authors who have published 81176 publications receiving 1248911 citations. The organization is also known as: Tongji & Tóngjì Dàxué.

Magnetic ordered mesoporous copper ferrite as a heterogeneous Fenton catalyst for the degradation of imidacloprid

Abstract: Highly ordered mesoporous copper ferrite (meso-CuFe2O4) with high surface area and large pore size was successfully fabricated and firstly proposed as a heterogeneous Fenton catalyst. It was synthesized through the nanocasting strategy by using KIT-6 as hard template. The morphology and physicochemical properties of meso-CuFe2O4 were characterized by SEM, TEM, XRD, XPS, FT-IR, Raman spectra, etc. The obtained results showed that the surface area and the pore size of meso-CuFe2O4 were 122 m2 g−1 and 9.2 nm, respectively. The meso-CuFe2O4 presented excellent catalytic activity for the degradation of imidacloprid, achieving almost complete removal of 10 mg L−1 imidacloprid after 5 h at the reaction conditions of 0.3 g L−1 catalyst and 40 mM H2O2. Kinetic analysis showed that the degradation of imidacloprid follows the pseudo-first order. The apparent rate constant for meso-CuFe2O4 was 1.0445 h−1, which was 1.5, 2 and 2.5 times than those of meso-CoFe2O4, con-CuFe2O4 and nano-Fe3O4, respectively. The amount of hydroxyl radical (OH) generated was directly proportional to the degradation efficiency of imidacloprid, suggesting the involvement of OH in oxidizing imidacloprid. The obtained results indicated that meso-CuFe2O4 presented the highest activity, which was not only due to its ordered mesoporous structure with high surface area and large pore size, but also assigned to the redox recycle of Fe2+/Fe3+ and Cu+/Cu2+ in meso-CuFe2O4. The special effect of Cu was discussed in terms of the thermodynamically favorable Fe3+ reduction by Cu+, regenerating the active species Fe2+. The meso-CuFe2O4 presented very low iron leaching (<1 ppm) even in acidic condition and retained almost its high catalytic activity after 5 consecutive runs. Besides, meso-CuFe2O4 possessed medium saturation magnetization, which had provided a potential advantage for the recovery and reuse of catalyst.

Enhanced catalytic degradation of methylene blue by α-Fe2O3/graphene oxide via heterogeneous photo-Fenton reactions

Abstract: Novel hybrid nanostructures or nanocomposites are receiving increasing attention due to their newly evolved properties. In this work, α-Fe 2 O 3 anchored to graphene oxide (GO) nanosheet (α-Fe 2 O 3 @GO) was synthesized through a facile hydrolysis process and its photo-catalytic performances and durability in heterogeneous Fenton system were fully evaluated. The decolorization rates of methylene blue in α-Fe 2 O 3 @GO + H 2 O 2 + UV system within a wide pH range were approximately 2.9-fold that of classical Degussa P25 TiO 2 + UV and 2.4-fold that of α-Fe 2 O 3 + H 2 O 2 + UV. This enhanced decolorization of methylene blue (MB) in α-Fe 2 O 3 @GO + H 2 O 2 + UV system were attributed to the unique incorporation of GO into the catalyst which not only mediated the morphology of active sites α-Fe 2 O 3 nanoparticles but also offered high electron conductivity and electrostatic attraction between negatively charged GO with positively charged MB. High efficiencies of degradation were achieved on various surface charged organic pollutants (around 96–100%), such as cationic compounds of MB and rhodamine B (RhB), anionic compound Orange II (OII) and Orange G (OG), neutral compounds of phenol, 2-nitrophenol (2-NP) and endocrine disrupting compound 17β-estradiol (E2). The dominant reactive oxygen species (ROS) responsible for decolorization, such as hydroxyl radicals ( OH) and superoxide anion radicals (O 2 − ) generated by activation of H 2 O 2 on the surface of α-Fe 2 O 3 @GO were detected and quantified by free radical quenching methods. The possible degradation mechanism of MB involved the rupture of phenothiazine ring by desulfurization and the rupture of phenyl ring due to the attack of ROS, which was analyzed by LC/MS/MS. The reduction of MB and its intermediates was consistent with the decreasing trend of the acute toxicity towards luminous bacteria with the increasing irradiation time. The results lay a foundation for highly effective and durable photo-Fenton technologies for organic wastewater within wider pH ranges than the conventional photo-Fenton reaction.

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

Abstract: Summary Background Icotinib, an oral EGFR tyrosine kinase inhibitor, had shown antitumour activity and favourable toxicity in early-phase clinical trials. We aimed to investigate whether icotinib is non-inferior to gefitinib in patients with non-small-cell lung cancer. Methods In this randomised, double-blind, phase 3 non-inferiority trial we enrolled patients with advanced non-small-cell lung cancer from 27 sites in China. Eligible patients were those aged 18–75 years who had not responded to one or more platinum-based chemotherapy regimen. Patients were randomly assigned (1:1), using minimisation methods, to receive icotinib (125 mg, three times per day) or gefitinib (250 mg, once per day) until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival, analysed in the full analysis set. We analysed EGFR status if tissue samples were available. All investigators, clinicians, and participants were masked to patient distribution. The non-inferiority margin was 1·14; non-inferiority would be established if the upper limit of the 95% CI for the hazard ratio (HR) of gefitinib versus icotinib was less than this margin. This study is registered with ClinicalTrials.gov, number NCT01040780, and the Chinese Clinical Trial Registry, number ChiCTR-TRC-09000506. Findings 400 eligible patients were enrolled between Feb 26, 2009, and Nov 13, 2009; one patient was enrolled by mistake and removed from the study, 200 were assigned to icotinib and 199 to gefitinib. 395 patients were included in the full analysis set (icotinib, n=199; gefitinib, n=196). Icotinib was non-inferior to gefitinib in terms of progression-free survival (HR 0·84, 95% CI 0·67–1·05; median progression-free survival 4·6 months [95% CI 3·5–6·3] vs 3·4 months [2·3–3·8]; p=0·13). The most common adverse events were rash (81 [41%] of 200 patients in the icotinib group vs 98 [49%] of 199 patients in the gefitinib group) and diarrhoea (43 [22%] vs 58 [29%]). Patients given icotinib had less drug-related adverse events than did those given gefitinib (121 [61%] vs 140 [70%]; p=0·046), especially drug-related diarrhoea (37 [19%] vs 55 [28%]; p=0·033). Interpretation Icotinib could be a new treatment option for pretreated patients with advanced non-small-cell lung cancer. Funding Zhejiang Beta Pharma (China), the Chinese National Key Special Program for Innovative Drugs, the 863 Project, and Zhejiang Provincial Key Special Program.

Circular RNA ciRS-7—A Promising Prognostic Biomarker and a Potential Therapeutic Target in Colorectal Cancer

Abstract: Purpose: Colorectal cancer is one of the most common malignancies worldwide. Recently, a novel circular RNA, ciRS-7, was proposed to be a potential miR-7 sponge. As miR-7, a putative tumor-suppressor, regulates the expression of several important drivers of colorectal cancer, we analyzed the clinical significance of ciRS-7 in colorectal cancer patients.Experimental Design: Initially, we evaluated the expression levels of ciRS-7 in a training cohort comprising of 153 primary colorectal cancer tissues and 44 matched normal mucosae. We subsequently confirmed its clinical relevance in an independent validation cohort (n = 165), and evaluated the effect of ciRS-7 on miR-7, and its target genes EGFR and RAF1. Functional analyses were performed in cell lines and an animal model to support clinical findings.Results: Our data revealed that ciRS-7 was significantly upregulated in colorectal cancer tissues compared with matched normal mucosae (P = 0.0018), and its overexpression was associated with poor patient survival (P = 0.0224 and 0.0061 in the training and validation cohorts, respectively). Multivariate survival analysis revealed that ciRS-7 emerged as an independent risk factor for overall survival (P = 0.0656 and 0.0324 in the training and validation cohorts, respectively). Overexpression of ciRS-7 in HCT116 and HT29 cells led to the blocking of miR-7 and resulted in a more aggressive oncogenic phenotype, and ciRS-7 overexpression permitted the inhibition of miR-7 and subsequent activation of EGFR and RAF1 oncogenes.Conclusions: CiRS-7 is a promising prognostic biomarker in colorectal cancer patients and may serve as a therapeutic target for reducing EGFR-RAF1 activity in colorectal cancer patients. Clin Cancer Res; 23(14); 3918-28. ©2017 AACR.